Bluejay Diagnostics, Inc. (BJDX) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Bluejay Diagnostics reported revenue of $0. Net income was -$6.8M, or -$15.25 per diluted share. Operating activities generated -$6.1M of cash, leaving -$6.2M of free cash flow. At fiscal year end, Bluejay Diagnostics held $7.1M in total assets against $1.1M in total liabilities, including $5.2M of cash and equivalents.
Open the full interactive Bluejay Diagnostics financials → Quarterly statements, key ratios, valuation history and price charts.
Bluejay Diagnostics Key Stats
| Share Price | $0.83 |
|---|---|
| Market Cap | $1.7M |
| 52-Week Range | $0.76 – $14.00 |
| Shares Outstanding | 2.1 million (basic, 2026 Q2) |
Bluejay Diagnostics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $249,040 | — | $0 | $0 |
| Cost of Goods Sold | — | $200,129 | — | — | — |
| Gross Profit | — | $48,911 | — | — | — |
| Operating Income | -$3.2M | -$9.3M | -$10.3M | -$7.2M | -$7.0M |
| Pre-Tax Income | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| Net Income | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| Diluted EPS | -$13120.00 | -$14720.00 | -$14528.00 | -$456.76 | -$15.25 |
Bluejay Diagnostics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.6M | -$1.4M | -$1.9M | -$2.3M |
| Diluted EPS | -$4.04 | -$3.18 | -$1.95 | -$1.12 |
Bluejay Diagnostics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $19.0M | $10.1M | $2.2M | $4.3M | $5.2M |
| Current Assets | $20.7M | $11.8M | $3.2M | $4.9M | $5.5M |
| Total Assets | $21.0M | $13.5M | $4.9M | $6.7M | $7.1M |
| Current Liabilities | — | $1.6M | $1.8M | $810,368 | $1.1M |
| Total Long-Term Debt | $10,000 | — | — | — | — |
| Total Liabilities | $637,162 | $2.0M | $2.0M | $927,924 | $1.1M |
| Shareholders' Equity | $20.4M | $11.5M | $2.9M | $5.7M | $6.0M |
Bluejay Diagnostics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$4.4M | -$7.7M | -$8.3M | -$7.8M | -$6.1M |
| Cash From Investing | -$23,947 | -$1.2M | -$704,166 | -$306,783 | -$173,735 |
| Cash From Financing | $22.5M | $8,075 | $1.1M | $10.2M | $7.1M |
| Free Cash Flow | -$4.4M | -$8.9M | -$9.0M | -$8.1M | -$6.2M |
Figures from Bluejay Diagnostics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bluejay Diagnostics financials page for every line item.
Bluejay Diagnostics Company Profile
| Ticker | BJDX |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Acton, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001704287 |
Frequently Asked Questions
What was Bluejay Diagnostics' revenue in fiscal 2025?
Bluejay Diagnostics (BJDX) reported revenue of $0 for fiscal 2025.
What is Bluejay Diagnostics' annual revenue history?
Bluejay Diagnostics' annual revenue by fiscal year: 2021: $0; 2022: $249,040; 2024: $0; 2025: $0.
What was Bluejay Diagnostics' net income in fiscal 2025?
Bluejay Diagnostics reported net income of -$6.8M for fiscal 2025.
What was Bluejay Diagnostics' earnings per share (EPS) in fiscal 2025?
Bluejay Diagnostics' diluted EPS was -$15.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bluejay Diagnostics generate in fiscal 2025?
Bluejay Diagnostics generated -$6.2M of free cash flow in fiscal 2025.
What was Bluejay Diagnostics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bluejay Diagnostics reported revenue of $0.
How many shares of Bluejay Diagnostics are outstanding?
Bluejay Diagnostics reported a weighted average of 2.1 million basic shares outstanding in 2026 Q2.
What is Bluejay Diagnostics' market cap?
Based on its latest closing price, Bluejay Diagnostics (BJDX) has a market capitalization of about $1.7M.
When does Bluejay Diagnostics' fiscal year end?
Bluejay Diagnostics' fiscal year end, as registered with the SEC, is December 31.
Where is Bluejay Diagnostics headquartered?
Bluejay Diagnostics lists its business address in Acton, Massachusetts in its SEC filings.
Bluejay Diagnostics Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →